Agile Therapeutics (NASDAQ:AGRX) is up 13% postmarket and on the move after announcing the FDA approved its Twirla contraceptive patch – its first approved product.
Twirla is a once-a-week transdermal treatment with
a combined hormonal approach that delivers a 30 mcg daily dose of
ethinyl estradiol (a type of estrogen) and a 120 mcg daily dose of
levonorgestrel (a well-known progestin).
The patch can be worn on the abdomen, buttock or upper torso.
The approval followed a delayed decision from the FDA in November, to address questions coming from the advisory committee. It had a new action date of Feb. 16.
https://seekingalpha.com/news/3542425-agile-therapeuticsplus-13-on-twirla-approval
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.